A potential new treatment could cut high blood pressure by 15 points within days, a new clinical trial suggests. The drug, ...

Net Loss: BioXcel Therapeutics had a net loss of $7.3 million for the first quarter of 2025, compared to a net loss of $26.8 ...

Continuing aspirin use perioperatively during subdural hematoma surgery neither increases recurrence risk nor reduces ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

Scientists have discovered a promising new therapy for resistant high blood pressure, leading to a 15-point drop in systolic ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) ...

More than 50 years have passed since the discovery of fluoxetine, better known by its trade name Prozac. Together with the ...

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Oral ivarmacitinib was effective for the treatment of moderate to severe atopic dermatitis in adults and adolescents, ...